Theratechnologies Inc. (THTX)
NASDAQ: THTX · IEX Real-Time Price · USD
1.560
+0.020 (1.30%)
At close: Jul 19, 2024, 4:00 PM
1.660
+0.100 (6.41%)
Pre-market: Jul 22, 2024, 7:16 AM EDT
Theratechnologies Revenue
Theratechnologies had revenue of $60.71M in the twelve months ending May 31, 2024, with 2.85% growth year-over-year. Revenue in the quarter ending May 31, 2024 was $16.19M with 24.54% year-over-year growth. In the fiscal year ending November 30, 2023, Theratechnologies had annual revenue of $59.25M.
Revenue (ttm)
$60.71M
Revenue Growth
+2.85%
P/S Ratio
1.18
Revenue / Employee
$589,456
Employees
103
Market Cap
71.73M USD
Revenue Chart
* The company reports in CAD currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Nov 30, 2023 | 59.25M | -943.96K | -1.57% |
Nov 30, 2022 | 60.19M | 5.64M | 10.35% |
Nov 30, 2021 | 54.55M | 3.74M | 7.36% |
Nov 30, 2020 | 50.81M | 3.28M | 6.90% |
Nov 30, 2019 | 47.53M | 13.53M | 39.81% |
Nov 30, 2018 | 34.00M | 4.94M | 17.01% |
Nov 30, 2017 | 29.06M | 21.94M | 308.18% |
Nov 30, 2013 | 7.12M | -6.54M | -47.88% |
Nov 30, 2012 | 13.66M | -985.25K | -6.73% |
Nov 30, 2011 | 14.64M | -16.44M | -52.90% |
Nov 30, 2010 | 31.09M | 14.56M | 88.06% |
Nov 30, 2009 | 16.53M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionTHTX News
- 12 days ago - Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024 - GlobeNewsWire
- 26 days ago - Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update - GlobeNewsWire
- 2 months ago - Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors - GlobeNewsWire
- 2 months ago - Theratechnologies Reports on its Annual Meeting of Shareholders - GlobeNewsWire
- 2 months ago - Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting - GlobeNewsWire
- 3 months ago - Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders - GlobeNewsWire
- 3 months ago - Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference - GlobeNewsWire
- 3 months ago - Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024 - GlobeNewsWire